<?xml version="1.0" encoding="UTF-8"?>
<p id="p0240">Other 3CLpro inhibitors, such as Cinanserin 
 <xref rid="b0420" ref-type="bibr">[84]</xref>, Flavonoids 
 <xref rid="b0425" ref-type="bibr">[85]</xref>, Cobicistat 
 <xref rid="b0430" ref-type="bibr">[86]</xref>, Atazanavir, Efavirenz, Ritonavir, Dolutegravir 
 <xref rid="b0435" ref-type="bibr">[87]</xref>, Thymopentin, Carfilzomib, Saquinavir 
 <xref rid="b0440" ref-type="bibr">[88]</xref>, Ledipasvir, and Velpatasvir 
 <xref rid="b0445" ref-type="bibr">[89]</xref> and PLP inhibitors, like Diarylheptanoids 
 <xref rid="b0450" ref-type="bibr">[90]</xref>, Grazoprevir, Telaprevir, Boceprevir 
 <xref rid="b0455" ref-type="bibr">[91]</xref>, Darunavir 
 <xref rid="b0460" ref-type="bibr">[92]</xref>, and Formoterol chloroquine 
 <xref rid="b0465" ref-type="bibr">[93]</xref> are other potential approaches to combat SARS-CoV-2, but their efficacy remains to be tested.
</p>
